Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for ...

The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb ...

“Traditional network deployments demand labor-intensive configuration and validation. Nile Nav automates these steps, ...

Ahmedabad: Zydus, a discovery-based, global pharmaceutical company has announced that the U.S. Food and Drug Administration ...

Pankaj Patel's Cadila Healthcare made news claiming to be first Indian pharma firm to have discovered a new combination drug for diabetics. Lipaglyn, a drug that controls both blood sugar and ...

India-origin Pankaj Patel is soon going to join the executive leadership team of global IT giant Cisco, which has restructured its top management recently under the guidance of CEO Chuck Robbins.

Zydus Lifesciences added 1.10% to Rs 987.60 after the company said that the USFDA had granted orphan drug designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic ...

As planned and announced at the start of 2016, Pankaj Patel, Cisco former executive vice president, chief development officer and head of global engineering under previous CEO John Chambers ...

“Every dollar invested will be scrutinized, demanding you to paint a larger picture about how your vision aligns with clear business priorities of your target audience,” says CEO Pankaj Patel ...

Zydus Lifesciences announced that the USFDA granted Orphan Drug Designation to Usnoflast, a novel oral NLRP3 inhibitor, for ...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health ...

Nile, the pioneer of a new breed of enterprise network solutions aimed at securing organizations from cyberattacks and automating daily operations, today announced a fundamental reimagining of how a ...